We Happy Few: Therapeutic Perceptual Modification, Regulatory Pathway Precedent, and the Governance Gap in Cloud-Rendered Reality

Abstract

We analyze an emergent governance challenge arising from the convergence of three maturing capabilities: real time 3D world generation models capable of producing spatially consistent environments from single images, consumer AR wearables with integrated cameras and displays, and AI driven behavioral and emotional modeling. We argue that these capabilities, when combined, enable a qualitatively new category of intervention: continuous modification of a user’s perceptual experience of their physical environment, rendered in real time and adapted to their emotional state. We further argue that legitimate therapeutic applications of this capability will enter the FDA regulatory pipeline within the near term, using the De Novo pathway established by EndeavorRx (DEN200026) and RelieVRx (DEN210014) as precedent. While we explicitly support the clinical evaluation of such interventions on their therapeutic merits, we identify five structural properties of cloud rendered perceptual modification that distinguish it from all previously cleared digital therapeutics: remote mutability, platform dependency, perceptual opacity, cultural encoding in training data, and absence of patient side verifiability. We examine the historical pattern of therapeutic scope expansion (from indicated use to consumer wellness product) across pharmaceutical and digital therapeutic domains and argue that the delivery mechanism’s unique properties require governance frameworks that do not yet exist. We conclude with specific recommendations for regulatory, clinical, and technical safeguards.